MENU
IONS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

IONS stock forecast, quote, news & analysis

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs... Show more

Industry: #Biotechnology
Interact to see
Advertisement
A.I.Advisor
published price charts
IONS
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for IONS with price predictions
Oct 13, 2026

IONS in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 14, 2026

IONS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 36 cases where IONS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 78%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IONS's RSI Oscillator exited the oversold zone, 17 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for IONS just turned positive on October 02, 2026. Looking at past instances where IONS's MACD turned positive, the stock continued to rise in 38 of 51 cases over the following month. The odds of a continued upward trend are 75%.

Following a +1.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where IONS advanced for three days, in 192 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IONS as a result. In 68 of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 66%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IONS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.

The Aroon Indicator for IONS entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 52 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. IONS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 90 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IONS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.212) is normal, around the industry mean (26.782). IONS's P/E Ratio (555.556) is considerably higher than the industry average of (43.395). Projected Growth (PEG Ratio) (4.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (8.368) is also within normal values, averaging (437.542).

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.21B. The market cap for tickers in the group ranges from 58 to 133.74B. VRTX holds the highest valuation in this group at 133.74B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -7%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -17%. TCRT experienced the highest price growth at 307%, while MLEC experienced the biggest fall at -64%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 13%. For the same stocks of the Industry, the average monthly volume growth was 38% and the average quarterly volume growth was -5%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: 2 (-100 ... +100)
View a ticker or compare two or three
IONS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of antisense drugs

Industry Biotechnology

Industry
Biotechnology
Address
2855 Gazelle Court
Phone
+1 760 931-9200
Employees
1402
Web
https://www.ionis.com
IONS in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 14, 2026